17MAY

Thinnest US health bench faces PHEIC

3 min read

11:07UTC

Jay Bhattacharya holds NIH Director and acting CDC Director simultaneously; Brian Christine, an Alabama urologist, is the Senate-confirmed HHS Assistant Secretary for Health since October 2025.

← Back to WHO calls Ebola PHEIC, no treatment exists Jump to analysis ↓

ScienceDeveloping

Key takeaway

Three of the federal positions that ran 2018 Equateur have no permanent occupant today.

Brian Christine, an Alabama urologist Senate-confirmed in October 2025, holds the Assistant Secretary for Health post at the US Department of Health and Human Services, the second-ranking health official below the Secretary ¹. Jay Bhattacharya, confirmed as NIH Director in March 2025, has held the acting CDC Director role concurrently since shortly after confirmation. Bhattacharya posted on X in January 2024 that "the best pandemic preparedness playbook for the United States is making America healthy again" ²; the post remains the publicly stated approach.

When the CDC ran the 2018 Equateur response under Robert Redfield, the agency had a confirmed director, a confirmed FDA commissioner and a confirmed Office of the Assistant Secretary for Preparedness and Response head simultaneously. None of those three positions currently has a permanent occupant. An Assistant Secretary for Health from urology, paired with a single individual holding NIH and acting CDC, gives the federal public-health roster its thinnest senior bench of the post-2014 era at the first Bundibugyo PHEIC in history. The concurrent H5N1 pressure across Idaho dairy operations and Bangladesh surveillance sits on the same bench at the same time.

Deep Analysis

In plain English

In a health emergency, the United States has several key agencies: the Centers for Disease Control (CDC), the Food and Drug Administration (FDA), and the Office of the Assistant Secretary for Preparedness and Response (ASPR). Each normally has a Senate-confirmed director who can make major decisions and speak with authority. As of May 2026, none of those three positions has a confirmed permanent occupant. Jay Bhattacharya, the NIH Director, is also filling in as acting CDC head. The second-ranking health official, Brian Christine, is a urologist with no prior public health emergency role. That is the team managing the first Bundibugyo Ebola emergency in history, while also dealing with a bird flu surge in Idaho dairy farms {{EVREF:/t/pandemics-and-biosecurity/2/idaho-dairy-h5n1-1-to-59-herds-in-twelve-days/}}.

What could happen next?

Risk
Multi-threat concurrent pressure across the Bundibugyo PHEIC, Idaho H5N1, and Andes hantavirus, with no confirmed leadership at CDC, FDA, or ASPR, creates conditions where interagency resource allocation decisions may be delayed or uncoordinated.
Consequence
CDC's absence from the WHO AFRO release while present in the Africa CDC statement may reflect the acting leadership's difficulty committing field resources without confirmed authority to approve budgetary deployment.

Source Landscape

This story draws on neutral-leaning sources

Primary parallel: During the 2018 Equateur Ebola outbreak, confirmed senior US public health roles were held by Robert Redfield (CDC Director, confirmed March 2018), Scott Gottlieb (FDA Commissioner, confirmed May 2017), and Robert Kadlec (ASPR, confirmed August 2017). Three confirmed senior officials at CDC, FDA, and ASPR simultaneously provided clear interagency authority lines for the response. That outbreak was contained in three months.

Counter-parallel: During the early COVID-19 response in January-March 2020, Robert Redfield was confirmed as CDC Director and Alex Azar as HHS Secretary, giving the US a fully staffed leadership bench.

The US still missed its 14 January 2020 WHO early warning, failed to scale domestic testing until late March, and did not implement coordinated PPE logistics until mid-April. Confirmed leadership is a structural prerequisite for clear decision authority; it does not guarantee effective response execution.

Consensus view: Former HHS Assistant Secretary for Preparedness and Response Robert Kadlec, WHO held confirmed roles at ASPR under three administrations, observed in public commentary that the simultaneous absence of confirmed CDC Director, FDA Commissioner, and ASPR head means outbreak-response decisions must be escalated to the HHS Secretary level for any cross-agency coordination, adding decision latency at the moment outbreak response most requires speed.

Counter-view: Former FDA Commissioner Scott Gottlieb (AEI health policy fellow) wrote in the Wall Street Journal in April 2026 that acting and interim officials can be operationally effective when career staff infrastructure remains intact, and argued that the CDC's career epidemiology and emergency response staff at the agency level have more institutional capacity than any single confirmed director.

Gottlieb's position is that personnel gaps at Senate-confirmed level matter less than programmatic budget and workforce continuity.

Key tension: Whether the acting-official structure creates real decision-latency in a multi-threat environment (Bundibugyo PHEIC + Idaho H5N1 + Andes hantavirus) or whether Gottlieb's career-staff argument holds when all three threats compete for the same budget and interagency attention simultaneously.

Sources:Wikipedia / Senate records / CNN Politics·Wikipedia / Senate records / CNN Politics·Science-Based Medicine (citing Bhattacharya's X post)

Mentions:Jay Bhattacharya →Brian Christine →NIH →United States →Bangladesh →H5N1 →Idaho →Wall Street Journal →PHEIC →Alabama →World Health Organization →Bundibugyo ebolavirus →HHS →CDC →

First Reported In

Update #3 · WHO calls Ebola PHEIC, no treatment exists

Wikipedia / Senate records / CNN Politics· 17 May 2026

Read original →

Causes and effects

This Event

Thinnest US health bench faces PHEIC

Three of the federal positions that ran 2018 Equateur, the CDC Director, the FDA Commissioner and the ASPR head, have no permanent occupant at the first Bundibugyo PHEIC.

Led to

Kenyan court halts US quarantine site

The dual NIH/acting-CDC role (ID:3364) is part of the thin US public-health bench context for the unilateral quarantine and screening decisions.

Occurred 29 May 2026

Read story →

Different Perspectives

Germany (evacuation recipient)

Germany received the Bundibugyo outbreak's third international medical evacuation on 13 July, a US humanitarian worker infected in Bunia on 10 July. The evacuation, following a French doctor's 24 June departure and May's first US case, tests whether isolation and biocontainment protocols scale beyond DR Congo's own borders.

Pennsylvania Department of Public Health

PDPH retested and retracted a false-positive measles wastewater signal on 6 July, then confirmed and publicised a real airport exposure from 4 July, with commissioner Palak Raval-Nelson stressing there is no broad threat to the general public. The national count, 2,231 cases across 42 states by 9 July, is on pace to beat 2025's 2,289-case record before September.

World Health Organization

WHO published its first dedicated Blueprint on fungal disease and antifungal resistance on 1 July, estimating more than 300 million people suffer serious fungal disease annually. The Blueprint names the gap in WHO's own AMR strategy rather than waiting for an external audit to force the admission.

Africa CDC

Africa CDC issued a formal 11 July appeal for responder protection, training and psychosocial support after health-worker infections tripled from 34 to 112 in a month. The appeal repeats June's unmet call for a rapid Bundibugyo diagnostic test, showing the ask has shifted from tools to basic safety and pay.

Front-line health workers, Ituri Province

Health workers in Ituri Province walked off the job or threatened to strike over unpaid hazard pay and delayed salaries, even as responder infections tripled to 112 with 35 dead. Their absence narrows the isolation workforce the CDC's model says must reach 70% coverage to avoid a 20,000-case worst case.

ECDC

ECDC co-published the isolation and contact-tracing figures behind WHO's DON612, tracking Ituri's isolation rate rising from 35 to 44 percent while still rating EU/EEA import risk as very low. Brussels backs the WHO line against travel restrictions, the position France's own contact-tracing response, not the US entry ban, actually validated.